Aurinia Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aurinia Pharmaceuticals (AUPH).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$16Upside to Avg. PT-4.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	TD Cowen	Stacy Ku	PT Raise	Buy	$17→$18
Aug 7, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$15→$16
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Downgrade	Outperform→Market Perform	$15→$16
Nov 7, 2025	Jefferies	Maury Raycroft	Upgrade	Hold→Buy	$10→$21
Nov 5, 2025	RBC Capital	Douglas Miehm	Downgrade	Outperform→Sector Perform	$9→$15
Aug 1, 2025	RBC Capital	Douglas Miehm	PT Raise	Outperform	$8→$9
Jul 30, 2025	HC Wainwright & Co.	Arthur He	Assumes	Buy	$17
Sep 16, 2024	Cantor Fitzgerald	Olivia Brayer	Maintained	Overweight	$10
Sep 9, 2024	Cantor Fitzgerald	Olivia Brayer	Maintained	Overweight	$10
Sep 6, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$13
Mar 1, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$13
Feb 23, 2024	Cantor Fitzgerald	Olivia Brayer	PT Cut	Overweight	$12→$10
Feb 22, 2024	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$15→$13
Feb 16, 2024	RBC Capital	Douglas Miehm	PT Cut	Outperform	$13→$8

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18

TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $15 to $16.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16

Leerink Partners analyst Joseph Schwartz downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Market Perform and raises the price target from $15 to $16.

Benzinga Newsdesk

PRO
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Price Target to $21

Jefferies analyst Maury Raycroft upgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Hold to Buy and raises the price target from $10 to $21.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15

RBC Capital analyst Douglas Miehm downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Sector Perform and raises the price target from $9 to $15.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $9

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price target from $8 to $9.

Benzinga Newsdesk

Aurinia Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Aurinia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18

PRO
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

PRO
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16

PRO
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Price Target to $21

PRO
RBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15

PRO
RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $9

People Also Watch

People Also Watch

Aurinia Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Aurinia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18

PRORBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

PROLeerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16

PROJefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Price Target to $21

PRORBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15

PRORBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $9

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18

PRO
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

PRO
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16

PRO
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Price Target to $21

PRO
RBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15

PRO
RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $9